Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Zafgen (ZFGN) Competitors

Zafgen logo

ZFGN vs. MBX, RVNC, CKPT, AVTE, TSVT, SLRN, CYBN, BIOA, NLTX, and PROC

Should you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Procaps Group (PROC).

Zafgen vs. Its Competitors

MBX Biosciences (NYSE:MBX) and Zafgen (NASDAQ:ZFGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/AN/AN/AN/A
ZafgenN/AN/A-$45.41M-$1.07-2.99

In the previous week, MBX Biosciences had 1 more articles in the media than Zafgen. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Zafgen. MBX Biosciences' average media sentiment score of 1.91 beat Zafgen's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
MBX Biosciences Very Positive
Zafgen Neutral

MBX Biosciences' return on equity of 0.00% beat Zafgen's return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A N/A N/A
Zafgen N/A -51.34%-34.55%

70.4% of Zafgen shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by insiders. Comparatively, 14.2% of Zafgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MBX Biosciences presently has a consensus target price of $37.50, indicating a potential upside of 200.60%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than Zafgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zafgen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

MBX Biosciences beats Zafgen on 8 of the 9 factors compared between the two stocks.

Get Zafgen News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZFGN vs. The Competition

MetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$119.90M$812.96M$5.56B$9.05B
Dividend YieldN/A4.84%5.24%3.99%
P/E Ratio-3.331.1519.9620.26
Price / SalesN/A230.41419.56119.26
Price / CashN/A23.4426.2128.59
Price / Book2.376.328.035.65
Net Income-$45.41M-$27.99M$3.18B$249.15M

Zafgen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZFGN
Zafgen
N/A$3.20
+2.9%
N/A-57.8%$119.90MN/A-3.3338
MBX
MBX Biosciences
3.2437 of 5 stars
$11.71
+2.6%
$37.50
+220.4%
N/A$387.72MN/A0.0036
RVNC
Revance Therapeutics
2.762 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500
CKPT
Checkpoint Therapeutics
0.4639 of 5 stars
$4.26
flat
$4.33
+1.7%
N/A$370.71M$41K-2.3210
AVTE
Aerovate Therapeutics
N/A$9.99
+8.7%
N/A-80.2%$289.56MN/A-3.3420High Trading Volume
TSVT
2seventy bio
N/A$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
CYBN
Cybin
3.136 of 5 stars
$9.03
+7.7%
$86.00
+852.0%
N/A$207.79MN/A-2.0650News Coverage
Analyst Revision
High Trading Volume
BIOA
BioAge Labs
N/A$4.23
+2.4%
N/AN/A$151.65MN/A0.00N/A
NLTX
Neoleukin Therapeutics
N/A$14.95
-7.5%
N/A-44.2%$140.50MN/A-4.8190High Trading Volume
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.0%$107.18M$409.92M0.004,900Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ZFGN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners